calcimedica inc glp-1 receptor agonists weight management diabetes treatments GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review A Comprehensive Review of the

Appeal to consumer interest The approval comes amid social media hype around GLP-1 drugs and next-generation agents like retatrutide, which influencers tout as GLP3 promising even greater weight loss

BMJ 2023;382:p2019.Article 72

Expert Opin Pharmacother (2013) 14:228196

Oral administration is the fastest-growing route, because the traditional delivery method has shown therapeutic benefits

Footnotes Financial disclosure The authors are employees of Lane Clark and Peacock LLP, which advises life sciences organizations developing treatments for obesity

Payer Action Plan Monitor the Drug Pipeline: At this time, there is no action that payers need to take